BPC June 16 update

Acorda ACOR +54% Parkinson product launch; Rhythm RYTM +13% Approval

Price and Volume Movers

Acorda Therapeutics, Inc. (NASDAQ: ACOR) shares climbed today after it announced that its product, INBRIJA to treat Parkinson's disease, is now available in Germany. Acorda expects to start receiving revenue from the supply of the product during the second quarter of 2022. Shares closed up 54% at $0.61.

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) traded up ahead of the FDA decisions to approve its supplemental New Drug Application (sNDA) for IMCIVREE (setmelanotide) to treat obesity and control of hunger. Shares closed up 13% at $3.90. After-hours it announced a $100 million non-dilutive revenue interest financing agreement with HealthCare Royalty Partners.

Heart Test Laboratories, Inc. (NASDAQ: HSCS) continued to trade up today after its debut on the market yesterday. Heart Test’s initial public offering (IPO) was for 1,500,000 units of stock and a warrant at $4.25 per unit. Shares closed up 42% at $2.42.

Akero Therapeutics, Inc. (NASDAQ: AKRO) shares closed up 22% at $10.37 after it announced two financial deals totalling $125 million. One deal included a $25 million investment by Pfizer Inc. (NYSE: PFE) and the other included a $100 million loan from Hercules Capital, Inc.

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) shares closed up 20% at $0.97 after its President, Raul Rodriguez bought $688,000 worth of stock, at $0.69.

AC Immune SA (NASDAQ: ACIU) and the Roche Group (OTCQX: RHHBY) announced that its Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial of crenezumab did not demonstrate that treatment statistically significantly slow or prevent cognitive decline. AC Immune shares closed down 18% at $2.35.

Advancers

CompanyPriceChange
OMER
Omeros Corporation
$1.01 +1.01  +100%
CLVS
Clovis Oncology Inc.
$1.01 +1.01  +100%
MREO
Mereo BioPharma Group plc
$1.01 +1.01  +100%
BLTE
Belite Bio Inc
$1.01 +1.01  +100%
INDP
Indaptus Therapeutics Inc.
$1.01 +1.01  +100%
TYRA
Tyra Biosciences Inc.
$1.01 +1.01  +100%
BLCM
Bellicum Pharmaceuticals Inc.
$1.01 +1.01  +100%
CRTX
Cortexyme Inc.
$1.01 +1.01  +100%
AUPH
Aurinia Pharmaceuticals Inc
$1.01 +1.01  +100%
ELYM
Eliem Therapeutics Inc
$1.01 +1.01  +100%

Decliners

CompanyPriceChange
TALS
Talaris Therapeutics Inc.
$1.01 -1.01  -100%
AKUS
Akouos Inc.
$1.01 -1.01  -100%
FEMY
Femasys Inc.
$1.01 -1.01  -100%
CLDX
Celldex Therapeutics Inc.
$1.01 -1.01  -100%
PRVB
Provention Bio Inc.
$1.01 -1.01  -100%
EPIX
ESSA Pharma Inc.
$1.01 -1.01  -100%
ADIL
Adial Pharmaceuticals Inc
$1.01 -1.01  -100%
CDAK
Codiak BioSciences Inc.
$1.01 -1.01  -100%
LABD
Direxion Daily S&P Biotech Bear 3X Shares
$1.01 -1.01  -100%
PPBT
Purple Biotech Ltd.
$1.01 -1.01  -100%

Pipeline Database Updates

Drug Price Stage Catalyst Market Cap

ACIU – AC Immune SA
Crenezumab - (API ADAD)
Autosomal Dominant Alzheimer's Disease (ADAD

$3.37
-0.24  -7%
Phase 3 Phase 3 results from the Colombia trial (n=252) did not statistically significantly slow or prevent cognitive decline in patients treated. Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints, noted June 16, 2022.
$281.1 million

CYTK – Cytokinetics Incorporated
Reldesemtiv - (COURAGE-ALS OLE)
Amyotrophic lateral sclerosis (ALS)

$41.00
+1.71  +4%
Phase 3 Phase 3 OLE trial initiated, June 16, 2022.
$3.5 billion

FBIO – Fortress Biotech Inc.
Cosibelimab (CK-301)
Cutaneous squamous cell carcinoma (CSCC)

$0.80
-0.04  -5%
BLA Filing Phase 1 pivotal top-line data reported that trial met primary endpoint, noted January 25, 2022. Phase 1 interim efficacy results reported an objective response rate of 54.8%, noted June 16, 2022. BLA submission due in 4Q 2022.
$85.9 million

MBRX – Moleculin Biotech Inc.
WP1122
Healthy Volunteers, Covid-19

$1.47
+0.02  +1%
Phase 1a Phase 1a trial authorization, May 10, 2022. Phase 1a single ascending dose (SAD) cohort 1 data reported that treatment is safe and well-tolerated, noted June 16, 2022. Multiple ascending dose (MAD) cohort to commence after completion of at least 3 SAD dosing cohorts.
$42 million

RHHBY – Roche Holding AG ADR
GB1211 in combination with Tecentriq (atezolizumabe) - (GALLANT-1)
Non-small cell lung cancer (NSCLC)

$42.01
+0.30  +1%
Phase 2a Phase 2a trial enrollment initiated, noted June 16, 2022. Phase 2a topline data mid-2023.
$269 billion